계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Immunis
company
About
Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.
- Irvine,California,United States
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $10M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2018
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$10M
Immunis has raised a total of
$10M
in funding over 2 rounds. Their latest funding was raised on
Aug 3, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 3, 2022 | Series A | $10M | 1 |
|
— | Detail |
Investments
Number of Investments
Number of Lead Investments
1
0
Immunis has made 1 investments. Their most recent investment was on
May 3, 2017, when Swiftly raised $2.50M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
May 3, 2017
Swiftly
|
Series Unknown | $2.50M | Analytics | — |
Investors
Number of Lead Investors
Number of Investors
1
1
Immunis is funded by 1 investors.
Remiges Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
Employee Profiles
Number of Employee Profiles
2
Immunis has 2 current employee profiles, including
Board member Hans Keirstead
Board member
Executive
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
